Home Icon

Loading, Please Wait...

Predictive Technology Group Reports Fiscal Year 2019 Financial Results

1004 Days ago

Revenue increases 162% to $43.5 million with $3.5 million in positive cash flow from operations

SALT LAKE CITY, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED) (the Company), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, reports financial results for fiscal year 2019 ended June 30, 2019 and provides a business update.

Management Commentary

“Fiscal 2019 fourth quarter revenue up 88%, to $13.4 million, compared to fiscal 2018 fourth quarter, was an all-time quarterly high and capped a highly productive year, with revenue up 162% to $43.5 million and cash flow from operations of $3.5 million,” said Bradley Robinson, CEO of Predictive Technology Group. “Notably, fiscal Q4 marked our 11th consecutive quarter of sequential-quarter revenue growth.

“Over the past year we significantly strengthened our ability to support the successful development and commercialization of proprietary genetic-based diagnostic tests and services, while growing sales of human cell and tissue products,” he added. “We expanded our leadership and Board with highly qualified professionals, opened state-of-the-art laboratories and production facilities, and presented compelling data at leading industry conferences that further validate our genetic approach to develop cutting-edge diagnostics and related therapeutics at early points or intervention. Among highlights was our global infertility research collaboration with Thermo Fisher Scientific to use their market-leading next-generation sequencing technology and technical resources and expertise to commercialize current diagnostics and develop future comprehensive infertility diagnostic solutions. This partnership with a global diagnostics leader is a significant stride forward in securing a leadership role for Predictive in infertility diagnostics.

“In reviewing our diagnostics portfolio, we recently commercialized the PGxPLUS+™ test, which assists physicians in selecting the right medication for patients suffering from chronic pain. Additionally, preparations are underway to launch our genetic testing service for those experiencing infertility, FertilityDX, to select collaborators during the American Society for Reproductive Medicine conference in October,” Robinson said. “In addition to these launches, our near-term focus is on commercializing our endometriosis diagnostic test ARTguide™ and our human cell and tissue products, and on further improving products currently on the market.”

Fiscal Year 2019 and Recent Highlights

Predictive Laboratories

  • Entered into a global infertility research collaboration with Thermo Fisher Scientific focused on studying the genetic factors that underlie infertility in women. The collaboration combines Predictive’s innovative research and development capabilities with Thermo Fisher Scientific’s market-leading next-generation sequencing technologies and analytical capabilities to better understand the genetics of infertility to facilitate current commercialization and future development of more comprehensive diagnostic solutions.
  • Achieved a milestone with the collection of 2,500 DNA samples along with comprehensive medical records within five months of acquiring Clinical Laboratory Improvement Act (CLIA) operations in March 2019. The samples are being used to support development of personalized molecular diagnostics and clinical therapies.
  • Launched ARTguide, a proprietary genetic test for women experiencing infertility as a result of endometriosis and other genetic conditions, to select key opinion leaders in reproductive endocrinology. The Houston Fertility Institute, through its agreement with Predictive, continues to generate clinical utility data to demonstrate improved outcomes from using this test with patients receiving fertility treatment.
  • Launched PGxPLUS+, a pharmacogenomic test panel marketed to pain clinics for the evaluation of genetic factors that impact a patient’s response to pain medications.
  • Completed the acquisition and integration of operations for the following companies:
    ○ Taueret Laboratories, LLC, a provider of genetic testing and DNA analysis services through its CAP/CLIA-certified laboratory, providing for faster entry into the high-growth women’s health testing market with proprietary commercial products.
    ○ Inception Dx, which included its next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under CLIA.
    ○ Regenerative Medical Technologies, Inc., which included allogeneic stem cell product design, intellectual property, consented medical records from patients in 13 clinics, and clinical trial methodology for degenerative disc disease.
  • Announced personnel appointments for Predictive Laboratories including:
    ○ E. Robert Wassman, MD as Co-Laboratory Director. Dr. Wassman is a pioneer in the introduction of genetic testing and personalized medicine with over 35 years of experience.
    ○ Christine Seward, MS, CGC as Senior Vice President of Sales and Marketing, bringing extensive experience commercializing molecular diagnostics including products in reproductive medicine from her 16 years at Myriad Genetics.
    ○ Douglas S. Rabin, MD as Vice President of Medical Affairs, Women’s Health. Dr. Rabin has more than 25 years of experience in women's healthcare, including both clinical reproductive endocrinology, and obstetrics and gynecology.
    ○ Lesa Nelson as Chief Operations Officer and Debbie Dyckman as Director of Quality Control, with both joining from the former Taueret Laboratories.
  • Presented at leading industry conferences as follows:
    ○ New data demonstrating the genetic basis of endometriosis at the 2019 European Society of Human Reproduction and Embryology annual meeting. Whole exome sequencing was used to identify four genes with significant gene burden in more than 2,500 women with endometriosis. It was found that one in four women with endometriosis carry a mutation in one of these genes, whereas the frequency in the general population is only 8%.
    ○ New data at the Society for Reproductive Investigation meeting demonstrating the ability of the proprietary genetic test ENDORisk™ to differentiate patients with endometriosis from those without, with a high degree of sensitivity in the Caucasian population.
    ○ New scientific discoveries concerning the genetics of endometriosis at the 74th American Society for Reproductive Medicine Scientific Congress & Expo. The presentation, “Can Genetic Markers of Endometriosis Predict a Patient’s Responsiveness to Leuprolide Acetate,” presented by Kenneth Ward, MD was recognized with the ASRM Scientific Program Committee’s “Best in Clinical/Population Science Prize Paper” research award. 
  • Entered into a research collaboration with the Preeclampsia Foundation to expand the study of genetic factors associated with this condition. The study will advance the Foundation’s database of preeclampsia medical information and will be utilized by Predictive Laboratories to develop a proprietary test for the early detection of women at risk for preeclampsia.

Predictive Biotech

  • Appointed Jeff Acuff to the newly created position of Chief Commercial Officer. Mr. Acuff has more than 25 years of commercial and leadership experience and a deep knowledge of the healthcare industry with a record of successful execution in ortho-biologic sales, building high-performing teams and achieving exceptional results.
  • Completed buildout of a new 15,164 sq. ft. production laboratory and R&D facility that meets good manufacturing Practice (cGMP) and Good Tissue Practice (cGTP) requirements. The lab features an ISO 7 cleanroom and 18 ISO 5 production hoods.

Corporate Developments

  • Expanded and strengthened the Company’s Board of Directors as follows:
    ○ John E. Sorrentino as Chairman of the Board in addition to his role as Chair of the Company’s Scientific Advisory Board. Mr. Sorrentino has more than 35 years of life sciences executive experience including 15 years in leadership positions at Wyeth/Pfizer.
    ○ Senator Orrin G. Hatch, Ronald Barhorst and Jay M. Moyes as directors, bringing exceptional industry, public affairs, financial and governance experience and expanding Board membership to six, including four independent directors.
  • Appointed Charles Andres, JD, PhD to the Scientific Advisory Board. Dr. Andres leads the life sciences group at the law firm Wilson Sonsini Goodrich & Rosati’s Washington, DC office and has significant expertise in intellectual property, FDA/regulatory, transactions, business and government matters.
  • Integrated the sales and marketing team from FlagshipHealth Group, previously a consultant contractor, to support commercial activities for Predictive Biotech and Predictive Laboratories through combined domestic direct sales and a nationwide distributor network.
  • Submitted an application to Nasdaq to list the Company’s common stock.
  • Filed a Form 10 registration statement with the SEC making the Company subject to the reporting requirements of the Exchange Act, including the filing of annual reports on Form 10-K, quarterly reports on Form 10-Q and periodic reports on Form 8-K, among other requirements. 

Fiscal Year 2019 Financial Results

Revenue for fiscal 2019 was $43.5 million, up 162% from $16.6 million for fiscal 2018, with the increase primarily due to higher demand for human cell and tissue products. In fiscal 2019 the Company elevated its presence at trade shows, expanded sales headcount and added several new distributors resulting in sales to more U.S. clinics. 

Cost of goods sold for fiscal 2019 were $16.3 million, compared with $4.0 million for fiscal 2018 with the increase mainly due to an increase in the volume of products shipped, as well as increases in quality and regulatory costs, share-based compensation cost and facility costs.

Selling and marketing expenses for fiscal 2019 were $13.9 million, compared with $12.7 million for fiscal 2018. The increase was primarily due to higher commissions and personnel costs related to headcount as the Company continued to expand, partially offset by lower share-based compensation expense related to warrants issued in fiscal 2018 with no similar issuance in fiscal 2019.

General and administration expenses for fiscal 2019 were $18.2 million, compared with $5.8 million for fiscal 2018. The increase was primarily due to higher share-based compensation expense, as well as higher personnel costs and increased outside services costs mainly in connection with public company compliance.

R&D expenses for fiscal 2019 were $5.8 million, compared with $1.9 million for the prior fiscal year, with the increase primarily due to costs related to the development of diagnostic products, and continued development of human cell and tissue product manufacturing methods.

Depreciation and amortization expenses for fiscal 2019 were $9.2 million, compared with $4.6 million for fiscal 2018. The increase was primarily due to an increase in the intangible asset portfolio arising from business combinations, asset acquisitions and costs related to laboratory expansion.

Other loss for fiscal 2019 was $0.8 million, compared with other loss of $0.7 million for fiscal 2018. The change was primarily driven by higher losses from the equity method investment associated with the increasing ownership in Juneau Biosciences, LLC and a decrease in interest income, partially offset by the bargain purchase gain arising from the acquisition of Taueret Laboratories, LLC.

Net loss attributable to controlling interest for fiscal 2019 was $15.3 million, or $0.06 per share, compared with a net loss attributable to controlling interest for fiscal 2018 of $6.1 million, or $0.03 per share. 

Cash and cash equivalents as of June 30, 2019 were $1.6 million, compared with $1.2 million as of June 30, 2018. Cash provided by operating activities for fiscal year 2019 was $3.5 million, a significant improvement from cash used in operating activities of $0.3 million for the prior fiscal year. The increase in cash provided by operating activities for the year ended June 30, 2019 compared to the prior year was primarily due to a $2.1 million decrease in the year over year change in inventories, and a $2.5 million increase in the year over year change in accounts payable. These increases were partly offset by an increase in the year over year change in accounts receivable.

About Predictive Biotech, Inc.

Predictive Biotech, Inc., a Salt Lake City-based life sciences company formed in 2015, is a leader in human cell and tissue products for use in cellular therapies and regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive’s four main placental-derived and Wharton’s Jelly umbilical cord-derived products. Predictive Biotech’s current products are regulated by the FDA under 21 CFR part 1271 section 361 as minimally manipulated allografts intended for homologous use.

About Predictive Laboratories, Inc.

Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under CLIA. The group recently launched its novel test for women experiencing infertility, ARTguide, to selected collaborators. ARTguide is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Assisted Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.

Forward-Looking Statements

This release contains “forward-looking” statements that are based on present circumstances and on Predictive Technology Group’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements and any statements of the plans and objectives of management for future operations and forecasts of future growth and value, are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. Such forward-looking statements are made only as of the date of this release and Predictive Technology Group assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. The information in this press release should be read in conjunction with, and is modified in its entirety by, the Annual Report on Form 10-K (the “Form 10-K”) filed by the Predictive Technology Group with the Securities and Exchange Commission (the “SEC”) and all of the Company’s other public filings with the SEC (the “Public Filings”). In particular, the financial information contained herein is subject to and qualified by reference to the financial statements contained in the Form 10-K and Public Filings, the footnotes thereto and the limitations set forth therein. Investors may not rely on the press release without reference to the Form 10-K and the Public Filings.


LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com

Financial tables to follow

    Years ended June 30,
    2019     2018  
Current assets:            
Cash   $ 1,618,244     $ 1,206,139  
Accounts receivable, net of allowance for doubtful accounts of $687,064 and $ -     1,250,476       534,625  
Due from equity method investee     184,443       184,443  
Inventory     5,775,185       3,791,374  
Other current assets     103,080       17,551  
Total current assets     8,931,428       5,734,132  
Fixed assets, net of depreciation     6,974,441       773,870  
License agreements, net of amortization     18,062,315       20,962,620  
Patents, net of amortization     6,850,490       7,761,187  
Trade secrets, net of amortization     45,336,335       8,096,311  
Other intangible assets, net of amortization     383,931       -  
Equity method investments     51,717,719       55,392,622  
Goodwill     5,254,451       5,254,451  
Other long-term assets     67,075       12,000  
Total assets   $ 143,578,185     $ 103,987,193  
Current liabilities:            
Accounts payable   $ 4,943,178     $ 1,322,149  
Accrued liabilities     1,857,771       1,034,905  
Deferred revenue     469,376       -  
Capital lease obligation, current portion     504,488       -  
Subscription payable, current portion     6,300,000       4,409,390  
Total current liabilities     14,074,813       6,766,444  
Capital lease obligation     1,511,554       -  
Subscription payable     4,040,610       10,965,611  
Notes Payable     400,000       -  
Deferred tax liabilities     11,014,745       4,917,323  
Total liabilities     31,041,722       22,649,378  
Stockholders' equity:            
Common stock, par value $0.001, 273,761,955 and 247,624,403 shares issued and outstanding at June 30, 2019 and June 30, 2018; 900,000,000 shares authorized     273,762       247,624  
Additional paid-in capital     153,604,830       108,049,300  
Common stock subscriptions receivable     -       (1,025,000 )
Accumulated deficit     (41,102,849 )     (25,813,957 )
Total controlling interest     112,775,743       81,457,967  
Non-controlling interest     (239,280 )     (120,152 )
Total stockholders' equity     112,536,463       81,337,815  
Total liabilities and stockholders' equity   $ 143,578,185     $ 103,987,193  

    Years ended June 30,
    2019     2018  
Revenue   $ 43,493,589     $ 16,624,336  
Cost of goods sold, exclusive of depreciation & amortization shown below     16,293,553       3,971,255  
Operating expenses:            
Selling and marketing     13,937,512       12,680,741  
General and administrative     18,229,874       5,827,891  
Research and development     5,822,862       1,896,092  
Depreciation and amortization     9,150,184       4,573,534  
Total operating expenses     47,140,432       24,978,258  
Operating loss     (19,940,396 )     (12,325,177 )
Interest income (expense)     (17,504 )     199,953  
Bargain purchase gain     363,676       -  
Loss on equity method investment     (1,164,903 )     (899,950 )
Other expense     (22,584 )     -  
Total other loss     (841,315 )     (699,997 )
Loss before income taxes     (20,781,711 )     (13,025,174 )
Benefit from income taxes     5,357,413       6,894,407  
Net loss   $ (15,424,298 )   $ (6,130,767 )
Net loss non-controlling interest     119,128       63,411  
Net loss controlling interest & comprehensive loss   $ (15,305,170 )   $ (6,067,356 )
Weighted average common shares outstanding     265,526,265       240,781,490  
Basic & diluted loss per share   $ (0.06 )   $ (0.03 )

    Years ended June 30,
    2019     2018  
Cash flows from operating activities:                
Net loss   $ (15,424,298 )   $ (6,130,767 )
Adjustments to reconcile net loss to net cash provided (used) in operating activities:            
Depreciation and amortization     9,296,417       4,510,123  
Provision for bad debts     687,064       -  
Share based compensation     11,654,942       10,527,427  
Deferred income taxes     (5,415,912 )     (6,894,407 )
Losses on equity method investment     1,164,903       899,950  
Interest income paid in equity shares     -       (199,187 )
Gain on bargain purchase     (363,676 )     -  
Changes in operating assets and liabilities:            
Accounts receivable     (1,389,871 )     (692,305 )
Inventory     (1,438,887 )     (3,584,261 )
Prepaid expenses     (65,929 )     (11,941 )
Other assets     (55,075 )     54,665  
Accounts payable     3,552,848       493,838  
Accrued liabilities     822,869       737,866  
Deferred revenue     469,376       -  
Net cash provided by (used in) operating activities     3,494,771       (288,999 )
Cash flows from investing activities:            
Purchases of property and equipment     (2,708,446 )     (405,580 )
Purchases of intellectual property     -       (1,357,272 )
Issuance of note receivable to equity method investee     -       (300,000 )
Cash acquired from acquisitions, net     885,674       -  
Cash payments on equity method investee stock subscription     (2,084,391 )     (1,875,000 )
Capitalization of patent acquisition costs     -       (111,305 )
Net cash used in investing activities     (3,907,163 )     (4,049,157 )
Cash flows from financing activities:            
Cash proceeds from stock subscriptions     1,025,000       1,367,500  
Proceeds from issuance of common stock     -       1,440,743  
Proceeds from issuance of common stock warrants     -       1,767,850  
Proceeds from issuance of promissory note     400,000       -  
Principal payments on capital leases     (655,203 )     -  
Exercises of warrants for cash     50,000        
Exercises of stock options for cash     4,700       -  
Net cash provided by financing activities     824,497       4,576,093  
Net increase (decrease) in cash and cash equivalents     412,105       237,937  
Cash and cash equivalents at the beginning of the period   $ 1,206,139     $ 968,202  
Cash and cash equivalents at the end of the period   $ 1,618,244     $ 1,206,139  

We Are Diffrent
Is your business listed correctly on America’s largest city directory network of 1,000 portals? Find your City Portal